s a potentially useful anticancer modality, the oncolytic measles virus (MV) can selectively propagate and destroy cancerous tissue without causing excessive damage to the normal surrounding tissue. Derivatives of the Edmonston MV (MV-Edm) have shown significant antitumor activity and a remarkable safety record in preclinical models of cancer. For years of experience in immunology and oncology, Creative Biolabs has established a comprehensive platform called OncoVirapy™ for oncolytic virus development service. By virtue of OncoVirapy™, we are able to design, engineer and generate the most efficacious oncolytic measles viral vector and measles viral partic
Measles virus is a negative-strand which contains six genes that encode eight proteins, RNA virus with envelope belonging to the family of Paramyxoviridae. It enters the cells via the interaction of the surface H glycoprotein with the three identified receptors: signaling lymphocyte activation molecule, membrane cofactor protein (CD46), and nectin-4. The CD46 is ubiquitously present on nucleated primate cells but is overexpressed in tumors. Genetic modifications have enabled MV to evolve from a vaccine agent to a potential anticancer therapy. The monitoring purpose can be achieved by inserting green fluorescent protein (GFP) or carcinoembryonic antigen (CEA) before nucleoprotein (N) gene. Replacing the phosphoprotein (P) gene with wild-type phosphoprotein (wtP) gene or insert cytokine/chemokine, even immune checkpoint antibody between the hemagglutinin (H) and large protein (L) gene can arm MV. Tropism of the virus can be changed through H gene manipulation and antisense miRNA (miRT) in Fusion (F) gene. MV has demonstrated potent and tumor-specific oncolytic activity against a variety of cancer, and the promising results, as a consequence, in preclinical animal models and evidence of biological activity in early phase trials contribute to the great enthusiasm of cancer treatment.
Creative Biolabs provides various armed oncolytic measles viruses to achieve research and treatment purpose. The insertion of miRTs can highly improve the safety and specificity of our redesigned virus. The miRT includes but is not limited to miR-122T which is specific to hepatocellular carcinoma (HCC) cells, miR-182T which is specific to uveal melanoma (UM) cells. Arming with the siRNA and shRNA like siNotch1, shSurvivin, shMPP1 and shVEGF, and expressing the immune checkpoint antibody/immune modulation (PD-L1, CTAL-4) or the cytokine/chemokine (IL-12) can make polyfunctionality viral products. Tropism can be modified for more expansion therapeutic window as well. We also provide customized oncolytic measles virus and proof-of-concept validation study for the oncolytic virus, combining increasing experiences and knowledge of MV system with the OncoVirapy™ platform. Creative Biolabs commits to developing efficacious oncolytic measles virus and enabling wider applications in oncolytic virotherapy of cancers. Please don’t hesitate to contact us for more information and quotation.
Please feel free to contact us for a quote and further discussion with our scientists.